Table 3.

Prognostic factors by univariate and multivariate analyses for OS and BMFS.

Prognostic Factors	OS				BMFS
	Univariate analyses		Multivariate analyses[Backward Stepwise (Wald)]		Univariate analyses		Multivariate analyses[Backward Stepwise (Wald)]
	P	HR	P	HR	P	HR	P	HR
		(95% CI)		(95% CI)		(95% CI)		(95% CI)
Gender	0.685	0.859			0.844	1.097
		(0.413–1.786)				(0.436–2.759)
Age	0.042	0.976			0.077	0.97
		(0.952–0.999)				(0.939–1.003)
ECOG	0.334	0.81			0.948	1.02
		(0.529–1.241)				(0.57–1.824)
Primary tumor location	0.609	1.027			0.414	0.942
		(0.928–1.136)				(0.816–1.087)
Clinical T stage	0.019	1.329			0.183	1.226
		(1.047–1.687)				(0.893–1.683)
Dmax-T	0.111	1.071			0.031	1.125	0.025	1.133
		(0.984–1.166)				(1.011–1.251)		(1.016–1.263)
Clinical N stage	0.003	1.683	0.015	1.621	0.117	1.427
		(1.188–2.384)		(1.098–2.393)		(0.915–2.225)
Dmax-N	0.003	1.175	0.052	1.119	0.257	1.082
		(1.058–1.305)		(0.999–1.253)		(0.945–1.239)
Clinical TNM stage	0.003	1.422			0.168	1.243
		(1.128–1.792)				(0.912–1.693)
NAC
Regimen	0.262	0.904			0.435	0.902
		(0.757–1.078)				(0.697–1.168)
Cycles	0.98	1.002			0.635	1.057
		(0.841–1.194)				(0.842–1.326)
CC
Regimen	0.78	0.974			0.959	0.993
		(0.81–1.171)				(0.771–1.28)
Cycles	0.376	1.159			0.149	1.393
		(0.836–1.608)				(0.888–2.185)
AC
Regimen	0.03	0.793	0.043	0.801	0.252	0.861
		(0.643–0.977)		(0.646–0.993)		(0.667–1.112)
Cycles	0.094	0.876			0.681	1.042
		(0.75–1.023)				(0.855–1.271)
Dose of GTV (cGy)	0.493	1			0.722	1
		(1–1.001)				(0.999–1.001)
Short-term response	0.033	1.431	0.002	1.662	0.008	1.813	0.006	1.872
		(1.029–1.99)		(1.196–2.309)		(1.169–2.812)		(1.192–2.939)

AC, adjuvant chemotherapy; BM, brain metastasis; BMFS, brain metastasis-free survival; CC, concurrent chemotherapy; ECOG, Eastern Cooperative Oncology Group scoring; GTV, gross tumor volume; NAC, neoadjuvant chemotherapy; OS, overall survival.